UK Health Regulator Approves Higher Weekly Wegovy Dose to Expand Obesity Treatment Options
Britain’s Medicines and Healthcare products Regulatory Agency authorises up to 7.2 mg weekly of Novo Nordisk’s Wegovy for adults with obesity, offering potential for greater weight loss.
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for a higher weekly dose of Novo Nordisk’s weight-loss drug Wegovy, marking a significant development in the treatment of obesity for adult patients with a body mass index of 30 kg/m² or greater.
The new authorisation, allowing a maximum of 7.2 milligrams of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide per week, comes amid increasing demand for effective medical interventions in obesity management and follows positive data from late-stage clinical trials demonstrating enhanced weight-loss outcomes with the augmented dose.
Under the updated guidance, healthcare professionals may now escalate a patient’s treatment from the standard 2.4 mg weekly maintenance dose to a total of 7.2 mg weekly if greater weight-loss support is required.
The regimen involves administering three separate 2.4 mg injections on the same day, each spaced at least five centimetres apart and with needles changed between injections, as part of a comprehensive plan that includes dietary modification and increased physical activity.
The regulatory decision was informed by data from the STEP UP clinical programme, which showed that adults with obesity experienced meaningful reductions in body weight on the higher dose, with a favourable tolerability profile consistent with the known safety aspects of the existing formulation.
Novo Nordisk’s general manager for the UK welcomed the approval as an important step that gives clinicians greater flexibility to tailor treatment to patients’ individual needs, particularly for those who have reached a plateau in weight loss on the lower dose.
The move also aligns with broader regulatory momentum in Europe and other markets, where higher Wegovy doses are under review or have received positive opinions from authorities.
Pharmaceutical markets responded positively to the news, with Novo Nordisk’s shares rising on investor optimism over the expanded therapeutic potential of Wegovy.
As the obesity epidemic continues to challenge public health systems worldwide, expanded access to the enhanced dosing option represents a notable advance in evidence-based care for people living with obesity.
The new authorisation, allowing a maximum of 7.2 milligrams of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide per week, comes amid increasing demand for effective medical interventions in obesity management and follows positive data from late-stage clinical trials demonstrating enhanced weight-loss outcomes with the augmented dose.
Under the updated guidance, healthcare professionals may now escalate a patient’s treatment from the standard 2.4 mg weekly maintenance dose to a total of 7.2 mg weekly if greater weight-loss support is required.
The regimen involves administering three separate 2.4 mg injections on the same day, each spaced at least five centimetres apart and with needles changed between injections, as part of a comprehensive plan that includes dietary modification and increased physical activity.
The regulatory decision was informed by data from the STEP UP clinical programme, which showed that adults with obesity experienced meaningful reductions in body weight on the higher dose, with a favourable tolerability profile consistent with the known safety aspects of the existing formulation.
Novo Nordisk’s general manager for the UK welcomed the approval as an important step that gives clinicians greater flexibility to tailor treatment to patients’ individual needs, particularly for those who have reached a plateau in weight loss on the lower dose.
The move also aligns with broader regulatory momentum in Europe and other markets, where higher Wegovy doses are under review or have received positive opinions from authorities.
Pharmaceutical markets responded positively to the news, with Novo Nordisk’s shares rising on investor optimism over the expanded therapeutic potential of Wegovy.
As the obesity epidemic continues to challenge public health systems worldwide, expanded access to the enhanced dosing option represents a notable advance in evidence-based care for people living with obesity.
